Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Vivo Capital Raises $750 Million for US-China Fund

publication date: Mar 18, 2015
Vivo Capital, a US-China healthcare investment company, closed its eighth fund at $750 million, which was two times Vivo's previous fund that raised $375 million three years ago. Vivo expects to invest in later development stage drug and device companies in the US and revenue-stage companies in China, with a focus on helping companies in both countries forge cross-border partnerships. Vivo, which has offices in Palo Alto, Shanghai, Beijing and Chengdu, now has assets under management of over $1.7 billion. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital